Skip to main content
Equibles
SYRE logo

SYRE · Spyre Therapeutics, Inc. · Metrics

Track SYRE — free

Use SYRE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SYRE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$92.95 +1.55 (+1.70%) At close · Oct 21
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”
View the 10-Q filed Aug 4, 2026
Market Cap
$8.06B
Shares
88.17M
Volume · Oct 21 1.15M Avg daily vol (3M) 1.22M

SYRE metrics

61 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$92.95
Market cap
$8.06B

Price action

20 metrics
Price change (1W)
+13.6%
Price change (30D)
-0.7%
Price change (3M)
-11.0%
Price change (6M)
+28.2%
Price change (YTD)
+179.0%
Price change (1Y)
+289.1%
Trailing year
Price change (5Y)
—
52-week high
$108.92
52-week low
$22.18
Change from 52-week high
-16.1%
Change from 52-week low
+312.1%
Annualized volatility
66.4%
Annualized volatility (3M)
60.1%
Beta
1.8
RSI (14D)
56.6
Price vs SMA 50
-0.3%
Price vs SMA 200
+29.4%
Avg volume (3M)
1.22M
Relative volume
1.4
Average dollar volume
$111.29M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
88.17M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
6.8
reciprocal yield 14.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
367.4×
reciprocal yield 0.3%
EV / revenue historical average (5Y)
367.4×
reciprocal yield 0.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2020-02-24

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$201.34M
Net income (TTM)
−$178.92M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-25.06
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$9.15

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,085.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-16.2%
Return on assets
-15.3%
Debt / equity
—
Current ratio
18.5
EBITDA (TTM)
−$208.57M
Free cash flow (TTM)
—
Quick ratio
18.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$162.01M
Latest balance sheet
Cash & equivalents
$162.01M
Total assets
$1.17B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$208.94M
Capital expenditures (TTM)
$38,000
R&D (TTM)
$215.80M
SG&A (TTM)
—
Stock compensation (TTM)
$45.70M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
267
13F filer change QoQ
+67
Institutional ownership
109.4%
Conviction holders (share of 13F filers)
4.5%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+12.5%
Holder tenure
8.2
Price vs estimated holder cost
+123.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.4%

Short interest

3 metrics
Short interest
14.6%
Latest settlement · 8.9 days to cover
Days to cover
8.9d
Short-squeeze score
84 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$16.90M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1636282 CUSIP 00773J202 13F (30d) 16 filings 16 filers Visit website Investor relations